C4 Therapeutics (CCCC) vs Kyverna Therapeutics (KYTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
C4 Therapeutics (CCCC) has outperformed Kyverna Therapeutics (KYTX) over the past year, gaining 1.6% versus a loss of 39.9%. C4 Therapeutics is the larger company by market cap ($325.7 million vs $269.3 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CCCC | KYTX |
|---|---|---|
| Share price | $2.48 | $4.26 |
| Market cap | $325.67M | $269.33M |
| 1-day change | +1.64% | -2.52% |
| YTD return | +29.84% | -54.68% |
| 1-year return | +1.64% | -39.92% |
| 5-year return | -93.23% | — |
| EPS (TTM) | $-0.63 | $-2.75 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $35.95M | — |
| Revenue growth (YoY) | +1.02% | — |
| Net income (latest FY) | $-104.99M | $-161.31M |
| Operating margin | -320.53% | — |
| Net margin | -292.08% | — |
| 52-week high | $5.17 | $13.67 |
| 52-week low | $1.69 | $4.18 |
| Distance from 52-week high | -52.03% | -68.84% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +404.03% | +613.62% |
| Average volume | 2.57M | 867.28K |
| Shares outstanding | 131.32M | 63.22M |
| Employees | 104 | 172 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CCCC has outperformed KYTX by 41.6 percentage points over the past year.
About C4 Therapeutics
CCCC stock →C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 104 employees
About Kyverna Therapeutics
KYTX stock →Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and autoimmune diseases.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 172 employees
CCCC vs KYTX FAQ
Which is bigger, C4 Therapeutics or Kyverna Therapeutics?
C4 Therapeutics (CCCC) is larger, with a market capitalization of $325.67M compared with $269.33M for Kyverna Therapeutics (KYTX).
Which stock has performed better over the past year, CCCC or KYTX?
CCCC returned +1.64% over the past 12 months, compared with -39.92% for KYTX (price return, excluding dividends). Past performance does not predict future results.
Are C4 Therapeutics and Kyverna Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.